Herbal Monograph
Boswellia
Boswellia serrata Roxb. ex Colebr.
Burseraceae
The anti-inflammatory resin — ancient sacred incense meets modern 5-LOX inhibition science for joint and gut health.
Overview
Plant Description
Medium-sized to large deciduous tree, 8-15 m tall (occasionally up to 18 m), with a spreading crown and papery, peeling bark that flakes off in thin, ash-colored to greenish-brown sheets, revealing the smooth, greenish underbark beneath. Trunk often short and crooked, with multiple branching. Bark exudes an oleo-gum-resin when incised or naturally wounded, which solidifies into translucent to opaque, yellowish to amber-brown, tear-shaped or irregular lumps with a balsamic, warm, slightly lemony odor. Leaves are alternate, imparipinnately compound, 20-45 cm long, crowded at branch ends, with 17-31 leaflets; leaflets ovate to ovate-lanceolate, 2-8 cm long, serrate-crenate margins, pubescent when young. Flowers small, white, in axillary racemes appearing with or before new leaves. Fruit a three-valved drupe (pyrene), about 1 cm, containing 1-3 seeds. The tree is drought-deciduous, shedding leaves during the dry season.
Habitat
Dry, hilly regions of tropical and subtropical India, particularly in dry deciduous and tropical thorn forests. Grows on rocky, poor, shallow soils at elevations of 250-1200 m. Tolerates extreme heat and drought. Prefers well-drained, sandy or rocky slopes. Often found on hillsides and ridges in association with dry deciduous forest species. Annual rainfall range: 500-2000 mm, with pronounced dry season.
Distribution
Native to the Indian subcontinent, primarily the dry regions of central and western India: Rajasthan, Madhya Pradesh, Gujarat, Maharashtra, Jharkhand, Chhattisgarh, Bihar, and parts of the Western Ghats. Also found in parts of the Middle East and northeastern Africa. India is the primary commercial source of B. serrata resin. The wider Boswellia genus (approximately 20 species) extends across the dry regions of tropical Africa, the Arabian Peninsula, and the Indian subcontinent.
Parts Used
Oleo-gum-resin (Gummi-resina Olibani Indici; Salai Guggul)
Preferred: Standardized extract (capsule/tablet), crude resin for traditional preparations, tincture
The primary medicinal material. Harvested from incisions in the bark. Consists of approximately 30-60% resin (containing boswellic acids and other terpenoids), 5-10% essential oil (volatile fraction), and 21-35% gum (polysaccharides including arabinose and galactose). The resin fraction contains the pharmacologically active boswellic acids. Quality and boswellic acid content vary significantly by grade, tapping season, tree age, and geographic origin. Standardized extracts are preferred for clinical use.
Essential oil (steam-distilled from oleo-gum-resin)
Preferred: Steam-distilled essential oil for external/aromatherapy use
Steam-distilled essential oil contains monoterpenes (alpha-thujene, alpha-pinene, limonene, p-cymene) and sesquiterpenes but NOT boswellic acids (which are non-volatile triterpenes and do not distill over). Contains incensole and incensole acetate, which have demonstrated anxiolytic and antidepressant effects in animal models via TRPV3 receptor activation. Used in aromatherapy and traditional incense. Not a substitute for boswellic acid-containing extracts for anti-inflammatory indications.
Key Constituents
Boswellic acids (pentacyclic triterpenic acids — primary bioactive compounds)
Boswellic acids are the principal bioactive compounds responsible for boswellia's anti-inflammatory effects. Their primary mechanism is selective, non-competitive, non-redox inhibition of 5-lipoxygenase (5-LOX), which is unique among natural anti-inflammatory agents. Unlike NSAIDs (which inhibit COX-1/COX-2) or corticosteroids (which broadly suppress immune function), boswellic acids specifically target the 5-LOX pathway responsible for leukotriene synthesis. Leukotrienes (LTB4, LTC4, LTD4) are potent mediators of inflammation, bronchoconstriction, and vascular permeability. By selectively inhibiting 5-LOX without affecting COX pathways, boswellia avoids the gastrointestinal and cardiovascular side effects associated with NSAIDs. Additionally, boswellic acids inhibit human leukocyte elastase (HLE), NF-kB signaling, and complement activation, providing multi-target anti-inflammatory effects. The total boswellic acid content (typically six major boswellic acids) and particularly the KBA and AKBA content are the primary quality markers for standardized extracts. See Ammon 2006 and Abdel-Tawab 2011 for comprehensive mechanistic reviews.
Essential oil (volatile fraction)
Essential oil comprises 5-10% of the crude oleo-gum-resin. Over 200 volatile compounds have been identified across Boswellia species. The volatile fraction contributes to the aromatic, antimicrobial, and potentially psychoactive properties of frankincense but does NOT contain boswellic acids. The incensole/incensole acetate content is of particular pharmacological interest for potential neurological applications. Essential oil composition is highly variable between species, chemotypes, and geographic origins, making species identification and quality control essential.
Polysaccharides (gum fraction)
The gum fraction provides the water-soluble matrix of the oleo-gum-resin. While less pharmacologically studied than the boswellic acids, the polysaccharides may contribute to immunomodulatory effects and influence the bioavailability of the resin-bound boswellic acids. In traditional Ayurvedic preparations, the whole oleo-gum-resin is used, which includes the gum fraction.
Other terpenoids
Additional terpenoids beyond the boswellic acids contribute to the overall pharmacological profile of boswellia extracts. The synergistic activity of multiple terpenoids may explain why whole resin extracts sometimes show greater clinical efficacy than isolated AKBA, supporting a multi-constituent therapeutic model.
Herbal Actions
Reduces inflammation
The defining pharmacological action of boswellia. Boswellic acids are selective, non-competitive, non-redox inhibitors of 5-lipoxygenase (5-LOX), a mechanism unique among natural and most synthetic anti-inflammatory agents. 5-LOX catalyzes the first step in leukotriene biosynthesis from arachidonic acid. Leukotrienes (particularly LTB4, LTC4, LTD4, LTE4) are potent pro-inflammatory mediators involved in joint inflammation, bronchial asthma, inflammatory bowel disease, and vascular permeability. By selectively targeting 5-LOX without inhibiting COX-1 or COX-2, boswellia avoids the gastric mucosal damage and cardiovascular risks associated with NSAIDs. Additionally, boswellic acids inhibit NF-kB activation, TNF-alpha production, complement system activation (particularly C3 convertase), and human leukocyte elastase (HLE). This multi-target anti-inflammatory profile makes boswellia particularly valuable for chronic inflammatory conditions. Clinical evidence supports efficacy in osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, and chronic asthma.
[23, 24, 25]Relieves pain
Analgesic effects secondary to anti-inflammatory activity. Reduction of leukotriene-mediated inflammation at joint and tissue levels contributes to pain relief. Clinical trials in osteoarthritis demonstrate significant pain reduction within 7-90 days of treatment. The analgesic mechanism is anti-inflammatory rather than direct analgesic (i.e., boswellia does not block pain signaling directly like opioids or acetaminophen, but reduces the inflammatory mediators causing pain). Sengupta et al. 2008 demonstrated pain improvement as early as 7 days with enriched AKBA extract (5-Loxin).
[5, 6]Modulates and balances immune function
Modulates rather than simply suppresses immune function. Boswellic acids reduce pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) while preserving normal immune surveillance. Inhibition of complement system (C3 convertase) reduces complement-mediated tissue damage without inducing broad immunosuppression. Reduces autoimmune-mediated inflammation as demonstrated in inflammatory bowel disease and rheumatoid arthritis studies. The immunomodulatory profile is nuanced: boswellia shifts the immune response away from tissue-destructive inflammation while maintaining host defense capacity.
[8, 23]Prevents or slows oxidative damage to cells
Boswellic acids demonstrate free radical scavenging activity and reduction of oxidative stress markers in animal and in vitro studies. Inhibition of 5-LOX indirectly reduces oxidative stress by decreasing leukotriene-driven inflammatory cascades that generate reactive oxygen species. Supplementary to the primary anti-inflammatory action rather than a standalone therapeutic effect.
[23]Relieves smooth muscle spasm
Smooth muscle relaxant activity demonstrated in animal studies, particularly on bronchial and intestinal smooth muscle. Contributes to efficacy in asthma (bronchial relaxation) and inflammatory bowel disease (intestinal smooth muscle relaxation). Mechanism may involve reduction of leukotriene-mediated bronchoconstriction (LTC4, LTD4 are potent bronchoconstrictors) rather than direct spasmolytic activity on smooth muscle.
[10]Tightens and tones tissue, reduces secretions
Traditional Ayurvedic classification includes kashaya (astringent) taste. The gum-resin has mild astringent properties. Contributes to traditional use in diarrhea and dysentery. Not a primary therapeutic action in modern clinical application.
[14]Promotes the discharge of mucus from the respiratory tract
Traditional use in respiratory conditions includes expectoration of phlegm. The essential oil component contributes aromatic expectorant properties. Frankincense steam inhalation has been used traditionally for respiratory congestion. Clinical evidence is primarily from the asthma studies, where the benefit appears to derive more from anti-inflammatory and anti-leukotriene effects on the airways than from direct expectorant activity.
[10]Therapeutic Indications
Musculoskeletal System
Osteoarthritis (particularly knee OA — pain, stiffness, functional limitation)
The most extensively studied clinical indication for boswellia. Kimmatkar et al. 2003 RCT (n=30, crossover): boswellia extract significantly reduced knee pain, increased knee flexion, and increased walking distance compared to placebo (P<0.001). Sengupta et al. 2008 double-blind RCT (n=75): 5-Loxin (100 mg, enriched to 30% AKBA) significantly reduced pain and improved physical function scores at 90 days, with significant improvements detectable as early as 7 days. Sengupta et al. 2010 study of Aflapin (100 mg, enhanced-bioavailability boswellia extract) showed faster and greater pain reduction than 5-Loxin. Yu et al. 2020 meta-analysis of 7 RCTs confirmed significant improvement in pain and function. Mechanism: 5-LOX inhibition reduces leukotriene-driven cartilage degradation and synovial inflammation. Also inhibits matrix metalloproteinases (MMP-3, MMP-9) that degrade cartilage collagen. Some evidence suggests boswellia may have disease-modifying potential (not just symptomatic relief) by reducing cartilage breakdown markers.
[5, 6, 7, 13]Rheumatoid arthritis
Traditional Ayurvedic indication. Immunomodulatory and anti-inflammatory mechanisms are pharmacologically relevant to RA pathology. Sander et al. 1998 pilot study (n=37) reported symptomatic improvement. Etzel 1996 review discussed evidence for boswellia in chronic inflammatory diseases including RA. The anti-leukotriene and NF-kB inhibitory mechanisms address key RA pathological pathways. Evidence is less robust than for OA, and boswellia is best positioned as an adjunctive therapy in RA rather than a primary treatment.
[14, 23]Tendinitis and joint inflammation (general)
Anti-inflammatory mechanism is applicable to a broad range of musculoskeletal inflammatory conditions. Some smaller studies and traditional evidence support use for bursitis, tendinitis, and general joint inflammation. The anti-leukotriene mechanism is particularly relevant to conditions involving local tissue inflammation and edema. Often used in combination with other anti-inflammatory herbs (curcumin, willow bark) in clinical practice.
[23]Digestive System
Ulcerative colitis
Gupta et al. 1997 RCT (n=34): Boswellia serrata gum resin preparation (350 mg tid) for 6 weeks resulted in remission in 82% of boswellia patients compared to 75% of sulfasalazine controls (P=NS), suggesting non-inferiority to sulfasalazine. Gupta et al. 2001 confirmed benefit. Mechanism: leukotriene B4 is elevated in colonic mucosa of UC patients and drives neutrophil chemotaxis and mucosal inflammation. 5-LOX inhibition by boswellic acids directly targets this pathological mechanism. The NF-kB inhibitory effect also reduces pro-inflammatory cytokine expression in intestinal mucosa. Boswellia is most appropriate as an adjunctive therapy and should not replace standard UC treatments without medical supervision.
[8, 9]Crohn's disease
Gerhardt et al. 2001 RCT (n=102): Boswellia serrata extract (H15, 3600 mg/day) was compared to mesalazine (4500 mg/day) for maintaining remission in Crohn's disease. Boswellia was not inferior to mesalazine in terms of Crohn's Disease Activity Index reduction. While not a definitive study (underpowered for formal non-inferiority), it suggests boswellia may be a viable alternative or adjunct for Crohn's disease. As with UC, the 5-LOX inhibitory mechanism directly targets the leukotriene-driven mucosal inflammation characteristic of Crohn's disease.
[11]Collagenous colitis
Madisch et al. 2007 pilot RCT (n=31): Boswellia serrata extract (400 mg tid for 6 weeks) improved clinical remission rate compared to placebo in collagenous colitis. Small study requiring replication, but the anti-inflammatory mechanism is applicable to this condition.
[12]Respiratory System
Bronchial asthma (chronic management)
Gupta et al. 1998 double-blind RCT (n=40): Boswellia gum resin (300 mg tid for 6 weeks) resulted in significant improvement in 70% of asthma patients versus 27% improvement in placebo group. Improvement measured by disappearance of dyspnea, reduced frequency of attacks, and improvement in FEV1 and PEFR. Mechanism: leukotrienes C4, D4, and E4 (the 'slow-reacting substance of anaphylaxis') are potent bronchoconstrictors and mediators of airway inflammation. 5-LOX inhibition by boswellic acids directly targets leukotriene-mediated bronchoconstriction and airway inflammation. This is the same molecular target as the pharmaceutical leukotriene receptor antagonist montelukast (Singulair), though boswellia inhibits synthesis rather than receptor binding. Boswellia is used adjunctively with conventional asthma medications, not as a replacement.
[10, 23]Nervous System
Cerebral edema (peritumoral edema)
Boeker et al. 1997 and Winking et al. 2000 reported reduction of peritumoral cerebral edema with boswellia extract (H15, 3600 mg/day) in brain tumor patients, potentially allowing reduction of corticosteroid dose. The anti-edema effect is attributed to leukotriene inhibition reducing vascular permeability. This is a specialized clinical application requiring medical supervision and is not a standard herbal indication, but it illustrates the potency of boswellia's anti-leukotriene mechanism. The EMA has noted this area as requiring further study.
[23]Anxiety and mood support (via frankincense incense inhalation)
Moussaieff et al. 2008 demonstrated that incensole acetate (a diterpene from frankincense resin) activates TRPV3 channels and produces anxiolytic and antidepressant effects in animal models. This may partially explain the traditional use of frankincense incense in religious and meditative contexts for promoting calm and contemplation. Clinical evidence in humans is limited. This effect is attributed to the volatile/incensole fraction, not to the boswellic acids.
[26]Skin / Integumentary
Chronic inflammatory skin conditions
Boswellic acids have demonstrated anti-inflammatory effects relevant to skin conditions in preclinical studies. Some pilot studies and case reports suggest potential benefit in conditions with leukotriene involvement. Topical boswellia preparations have been studied for photoaging and inflammatory skin conditions. Evidence base is still developing for dermatological applications.
[23]Energetics
Temperature
warm
Moisture
dry
Taste
Tissue States
heat/excitation, damp/stagnation
In Ayurveda, Shallaki (boswellia) is described as having tikta (bitter), kashaya (astringent), and madhura (sweet) rasa (tastes), with ushna virya (warm potency) and katu vipaka (pungent post-digestive effect). It is considered tridoshic in moderation but primarily pacifies vata and kapha doshas while mildly increasing pitta at higher doses. The bitter and astringent tastes make it particularly suited for conditions involving excess kapha (accumulation, congestion) and vata (pain, degeneration). In Unani medicine, luban (frankincense) is classified as warm and dry in the second degree, used for conditions of cold, damp constitution. The resin's warming, drying, and anti-inflammatory properties are consistent across Ayurvedic, Unani, and Western energetic assessments. Western energetics: warm, dry, moving — indicated for chronic inflammatory conditions with tissue stagnation and degeneration.
Traditional Uses
Ayurveda
- Shallaki (boswellia): Primary traditional use for sandhivata (joint conditions including arthritis, joint pain, and joint swelling)
- Treatment of shvasa (asthma) and kasa (cough) — respiratory conditions with inflammation and phlegm
- Atisara (diarrhea) and pravahika (dysentery) — astringent and anti-inflammatory action on the gut
- Vrana (wound healing) — resin applied externally to promote healing of chronic wounds and ulcers
- Medoroga (obesity-related conditions) — as part of metabolic support formulations
- Component of classical formulations: Yogaraja Guggulu, Simhanada Guggulu (for joint conditions)
- Raktashodhaka (blood purifier) — used for conditions attributed to impure blood
- Dhupa (fumigation/incense) — burning the resin for purification of spaces, sacred rituals, and respiratory benefit
"Boswellia is described in the Sushruta Samhita (c. 600 BCE) as Shallaki, recommended for joint diseases, inflammatory conditions, diarrhea, and wound healing. Also described in the Charaka Samhita and Bhavaprakasha Nighantu. Classified under vatahara (vata-pacifying) herbs, making it particularly suited for degenerative and painful conditions associated with vata dosha. The Ayurvedic pharmacological profile (rasa, guna, virya, vipaka) supports its use in conditions of vata aggravation (pain, degeneration) and kapha accumulation (swelling, congestion). In the Ayurvedic tradition, shallaki is one of the primary herbs for maintaining healthy joint function and mobility."
Ancient Egyptian and Near Eastern traditions
- Sacred incense in temple rituals and religious ceremonies — one of the most valued aromatic substances in the ancient world
- Embalming and mummification — frankincense resin used as a preservative and aromatic agent
- Fumigation for purification of sacred spaces
- Treatment of wounds and skin conditions — resin applied externally
- Cosmetic preparations — kohl eyeliner made from charred frankincense
- Offering to the gods — frankincense was one of the most important temple offerings in ancient Egyptian religion
"Frankincense (from various Boswellia species) was among the most prized commodities in the ancient world. The Ebers Papyrus (c. 1550 BCE), one of the oldest known medical texts, references frankincense for various medicinal applications. Ancient Egyptian temples consumed vast quantities of frankincense, and the Land of Punt (likely modern Somalia/Eritrea) was a primary source. Queen Hatshepsut's famous expedition to Punt (c. 1470 BCE) specifically sought frankincense trees. The ancient incense trade routes connecting Arabia and East Africa to Egypt, Mesopotamia, Greece, and Rome were among the most important commercial networks of antiquity."
Biblical and Abrahamic religious traditions
- One of the gifts of the Magi to the infant Jesus (Matthew 2:11), alongside gold and myrrh — symbolizing divinity and priestly role
- Component of the sacred incense (ketoret) burned in the Tabernacle and Temple as described in Exodus 30:34-38
- Liturgical incense in Catholic, Orthodox, and Anglican Christian worship — continuous use spanning over 2000 years
- Mentioned in the Song of Solomon (4:6, 4:14) as a precious aromatic
"Frankincense (Hebrew: levonah; Greek: libanos; Latin: olibanum) holds profound significance across Abrahamic traditions. In the Hebrew Bible, it is an essential component of the ketoret (sacred incense) and of the showbread offering. The New Testament mentions it as one of three gifts brought by the Magi. Its continuous use in Christian liturgy for nearly two millennia represents one of the longest unbroken traditions of aromatic plant use in human culture."
Unani (Greco-Islamic) medicine
- Kundur/luban: Used for joint pain and inflammatory conditions
- Treatment of respiratory conditions including chronic cough and asthma
- Wound healing — resin applied externally or as a fumigant
- Memory and cognitive enhancement — traditional reputation as a brain tonic
- Treatment of diarrhea and dysentery
- Oral health — resin chewed for strengthening teeth and gums
"Known as kundur or luban in Unani medicine. Avicenna (Ibn Sina, 980-1037 CE) described frankincense in the Canon of Medicine for joint conditions, respiratory complaints, and wound healing. Classified as warm and dry in the second degree. Dioscorides (De Materia Medica, c. 70 CE) described frankincense for hemostasis, wound healing, and various inflammatory conditions. The Unani tradition emphasizes its warming, drying, and tissue-restoring properties."
Traditional African medicine
- Resin burned as fumigant for respiratory conditions and to purify living spaces
- Treatment of joint pain and rheumatic complaints
- Wound healing and skin conditions — resin applied topically
- Postpartum care — fumigation for new mothers
- Treatment of digestive complaints including diarrhea
- Oral hygiene — chewing resin for dental health
"Various Boswellia species (B. papyrifera, B. sacra/carterii, B. frereana) are used across East African traditional medicine systems in Somalia, Ethiopia, Eritrea, Sudan, and Kenya. The Somali frankincense trade has been a major economic activity for centuries. Traditional harvesters and healers maintain detailed knowledge of different resin grades and their specific medicinal applications. Frankincense fumigation is widely used in East African cultures for respiratory health, spiritual purification, and postpartum care."
Modern Research
5-LOX inhibition: unique mechanism of anti-inflammatory action
Foundational pharmacological research establishing boswellic acids, particularly AKBA and KBA, as selective, non-competitive, non-redox inhibitors of 5-lipoxygenase (5-LOX), the key enzyme in leukotriene biosynthesis.
Findings: Safayhi et al. 1992 first identified boswellic acids as 5-LOX inhibitors. AKBA is the most potent inhibitor (IC50 ~1.5 microM). The inhibition is non-competitive (does not compete with substrate binding) and non-redox (does not function by oxidation/reduction, unlike many LOX inhibitors). This mechanism is pharmacologically distinct from NSAIDs (COX inhibitors), corticosteroids (phospholipase A2 inhibitors), and zileuton (the only FDA-approved 5-LOX inhibitor, which acts by a redox mechanism). Boswellic acids also inhibit human leukocyte elastase (HLE), a serine protease that degrades connective tissue. Additional targets include NF-kB, TNF-alpha, IL-1beta, and complement C3 convertase. Abdel-Tawab et al. 2011 provided a comprehensive review of the pharmacokinetics and noted bioavailability challenges with AKBA.
Limitations: Much mechanistic work is from in vitro studies. In vivo tissue concentrations of boswellic acids at therapeutic doses in humans are not fully characterized. AKBA has poor oral bioavailability, raising questions about whether in vitro IC50 values are achievable in vivo. Some boswellic acids (beta-boswellic acid) may actually promote 5-LOX at certain concentrations, complicating the pharmacological picture.
Boswellia extract for osteoarthritis of the knee: RCT (Kimmatkar 2003)
Randomized, double-blind, placebo-controlled, crossover trial evaluating Boswellia serrata extract in 30 patients with osteoarthritis of the knee.
Findings: Patients received boswellia extract or placebo for 8 weeks, followed by washout and crossover. Boswellia treatment significantly reduced knee pain (P<0.001), increased knee flexion (P<0.001), increased walking distance (P<0.001), and reduced frequency of knee swelling. Radiological assessment showed no change, consistent with a symptomatic (anti-inflammatory) rather than structural effect over this short treatment period.
Limitations: Small sample size (n=30). Crossover design may have carryover effects despite washout period. Short treatment duration. Single-center study. Radiological endpoints did not show structural improvement (though the 8-week duration was likely too short to detect such changes).
[5]
5-Loxin (enriched AKBA extract) for osteoarthritis: RCT (Sengupta 2008)
Double-blind, randomized, placebo-controlled trial evaluating 5-Loxin (Boswellia serrata extract enriched to 30% AKBA) at two doses (100 mg and 250 mg) in 75 patients with osteoarthritis of the knee.
Findings: Both 5-Loxin doses significantly reduced pain and improved physical function compared to placebo at 90 days. Significant pain reduction was detectable as early as 7 days at the 250 mg dose. Both doses significantly reduced synovial fluid MMP-3 levels (a cartilage-degrading enzyme), suggesting potential disease-modifying activity beyond symptomatic relief. The 250 mg dose showed faster onset of action. WOMAC pain, stiffness, and function scores all improved significantly.
Limitations: Moderate sample size (n=75, 25 per group). Single-center study. 90-day duration limits assessment of long-term efficacy and safety. Industry-funded (Laila Nutraceuticals). MMP-3 as a biomarker is suggestive but not conclusive evidence of disease modification.
[6]
Boswellia serrata extract for ulcerative colitis: RCT (Gupta 1997)
Randomized, double-blind, controlled trial comparing Boswellia serrata gum resin preparation with sulfasalazine in 34 patients with chronic ulcerative colitis (grade II-III).
Findings: Patients received boswellia gum resin (350 mg tid, n=20) or sulfasalazine (1 g tid, n=10) for 6 weeks. Remission was achieved in 82% of boswellia patients and 75% of sulfasalazine patients, with no statistically significant difference between groups. Boswellia showed improvement in stool properties, histopathology, hemoglobin, serum iron, calcium, phosphorus, proteins, total leukocyte count, and eosinophil count. The comparable efficacy to a standard treatment suggests boswellia as a potential alternative or adjunct for UC.
Limitations: Very small sample size (n=34 with unequal allocation). No placebo arm. Short treatment duration (6 weeks). Single-center study. Did not assess maintenance of remission. Unequal group sizes (20 vs 10). Would need larger, multi-center replication.
[8]
Boswellia for bronchial asthma: RCT (Gupta 1998)
Double-blind, placebo-controlled trial evaluating Boswellia serrata gum resin (300 mg tid for 6 weeks) in 40 patients with bronchial asthma.
Findings: 70% of boswellia patients showed improvement (defined as disappearance of physical symptoms, decrease in attack frequency, improvement in FEV1 and PEFR) compared to 27% improvement in the placebo group. Improvement in lung function parameters (FEV1, PEFR, FVC) was significant. Eosinophil count and ESR decreased in the treatment group. The results are consistent with the anti-leukotriene mechanism, as leukotrienes (LTC4, LTD4, LTE4) are major mediators of bronchoconstriction and airway inflammation in asthma.
Limitations: Small sample size (n=40). Short treatment duration (6 weeks). Did not specify asthma severity classification. Outcome definitions were somewhat broad. Single-center study. Published in a regional journal. Requires larger, multi-center replication with more rigorous methodology.
[10]
Comprehensive review of boswellic acids: mechanisms and pharmacology (Ammon 2006)
Comprehensive narrative review of the pharmacological mechanisms, clinical evidence, and therapeutic applications of boswellic acids from Boswellia serrata.
Findings: Consolidated evidence for 5-LOX inhibition (selective, non-competitive, non-redox), HLE inhibition, NF-kB modulation, complement inhibition, and anti-proliferative activity. Reviewed clinical evidence across osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, asthma, and peritumoral cerebral edema. Concluded that boswellic acids represent a unique class of anti-inflammatory compounds with a clinically relevant mechanism targeting leukotriene biosynthesis. Highlighted the need for improved formulations to address bioavailability challenges.
Limitations: Narrative review (not systematic). Included studies of variable quality. Bioavailability challenges with AKBA were acknowledged but not fully resolved at time of publication.
[23]
Aflapin (enhanced-bioavailability boswellia extract) for osteoarthritis: RCT (Sengupta 2010)
Double-blind, randomized, placebo-controlled, comparative trial evaluating Aflapin (100 mg, a bioavailability-enhanced Boswellia serrata extract) versus 5-Loxin (100 mg, 30% AKBA) versus placebo in 60 patients with knee osteoarthritis.
Findings: Both Aflapin and 5-Loxin significantly improved pain and function compared to placebo. Aflapin showed faster onset and greater magnitude of improvement compared to 5-Loxin, attributed to its enhanced bioavailability formulation. Both actives significantly reduced MMP-3 levels in synovial fluid. The study supported the development of bioavailability-enhanced formulations to address the poor oral absorption of AKBA.
Limitations: Small sample size (n=60, 20 per group). 30-day treatment duration. Industry-funded. Single-center. Comparison between two proprietary products from the same manufacturer.
[7]
Meta-analysis of Boswellia serrata for osteoarthritis (Yu 2020)
Systematic review and meta-analysis of randomized controlled trials evaluating Boswellia serrata extracts for osteoarthritis symptoms.
Findings: Analysis of 7 RCTs confirmed that Boswellia serrata supplementation significantly improved pain and physical function in osteoarthritis patients compared to placebo. Effect sizes were clinically meaningful. Boswellia was well-tolerated with a favorable safety profile. The meta-analysis supported boswellia as an evidence-based complementary approach for OA management.
Limitations: Heterogeneity in boswellia preparations, doses, and standardization across trials. Most studies were small to moderate in size. Variable treatment durations. Potential publication bias.
[13]
Incensole acetate: psychoactive properties of frankincense via TRPV3 activation
Investigation of the psychoactive properties of incensole acetate, a diterpene found in frankincense resin, using animal behavioral models and receptor binding studies.
Findings: Moussaieff et al. 2008 demonstrated that incensole acetate activates TRPV3 (transient receptor potential vanilloid 3) cation channels, which are expressed in the brain. Administration produced anxiolytic effects in the elevated plus-maze test and antidepressant effects in the forced swim test in mice. The TRPV3-mediated mechanism provides a potential molecular basis for the traditional use of frankincense incense in religious and contemplative practices to induce calm and elevated mood.
Limitations: Animal study only; human translation not established. Incensole acetate content varies significantly between Boswellia species and resin preparations. The doses used may not reflect amounts delivered through incense inhalation. TRPV3 expression and function in the human brain require further characterization.
[26]
Preparations & Dosage
Standardized Extract
Strength: Standardized to 30-65% total boswellic acids and/or specified AKBA content (ideally >10% AKBA)
Commercially prepared Boswellia serrata extract standardized to boswellic acid content. Multiple proprietary formulations available: standard extracts (typically standardized to 30-65% total boswellic acids), 5-Loxin (enriched to 30% AKBA), Aflapin/ApresFlex (bioavailability-enhanced extract containing B. serrata extract with non-volatile oil). Select products with documented boswellic acid content and, ideally, specified AKBA concentration.
Standard extract (30-65% boswellic acids): 300-500 mg, 2-3 times daily (total 600-1500 mg/day). 5-Loxin (30% AKBA): 100-250 mg daily. Aflapin/ApresFlex: 100 mg daily. Doses in clinical trials have ranged from 100 mg to 3600 mg daily depending on extract standardization.
2-3 times daily with meals (food enhances absorption of lipophilic boswellic acids)
Clinical trials typically 4-12 weeks. Traditional Ayurvedic use supports long-term administration for chronic conditions. Effects may take 1-4 weeks to become apparent; 8-12 weeks for full clinical benefit in OA.
Not well-established. Some traditional Ayurvedic texts describe pediatric use; consult qualified practitioner. Not recommended for children under 12 without professional supervision.
The most clinically studied preparation form. Standardization is important because boswellic acid content varies widely in crude resin (6-12% total boswellic acids in raw oleo-gum-resin). Taking with food (particularly fat-containing meals) significantly improves bioavailability of the lipophilic boswellic acids. The enhanced-bioavailability formulations (Aflapin/ApresFlex) were developed specifically to address poor AKBA absorption and may allow lower total doses. When selecting a product, look for third-party testing and specified boswellic acid profile rather than relying solely on claimed total boswellic acid percentages.
capsule-powder
Strength: Crude powdered oleo-gum-resin (unstandardized or partially standardized)
Fill capsules with finely powdered Boswellia serrata oleo-gum-resin. This is the form closest to the traditional Ayurvedic preparations used in older clinical trials (Gupta 1997, 1998, Kimmatkar 2003).
300-400 mg crude resin powder, 3 times daily (total 900-1200 mg/day). This was the approximate dose used in the Gupta UC trial (350 mg tid) and Gupta asthma trial (300 mg tid).
3 times daily with meals
6-8 weeks minimum for clinical effect. May be used long-term for chronic conditions.
Not established. Consult Ayurvedic practitioner for children.
Crude resin powder contains approximately 6-12% total boswellic acids along with the gum and essential oil fractions. While less standardized than concentrated extracts, the whole resin may provide complementary compounds (gum polysaccharides, essential oil components, additional terpenoids) that contribute to the overall therapeutic effect. The Gupta UC and asthma trials used this type of preparation with positive results. However, the lower boswellic acid concentration means higher doses are needed compared to standardized extracts.
Tincture
Strength: 1:5, 60-70% ethanol
Macerate powdered Boswellia serrata oleo-gum-resin in 60-70% ethanol at a ratio of 1:5 for 2-4 weeks. Shake daily. Press and filter. The resin component requires higher alcohol concentration for adequate extraction of boswellic acids.
2-4 mL (approximately 40-80 drops), 3 times daily
3 times daily
As needed for chronic inflammatory conditions
Not established. Alcohol-based preparations generally not recommended for children.
Tincture is a less common preparation form for boswellia compared to capsules/tablets, but it is used in Western herbal practice. The higher alcohol percentage is necessary to dissolve the resinous boswellic acids. The gum fraction is not well-extracted by alcohol and will separate out. Tincture may be added to anti-inflammatory formulations alongside other herbs (e.g., turmeric, devil's claw, willow bark).
[14]
Decoction
Strength: 3-5 g crude oleo-gum-resin per 200-250 mL water
Traditional Ayurvedic preparation: Simmer 3-5 g of coarsely powdered oleo-gum-resin in 200-250 mL water for 15-20 minutes. Strain. The gum fraction will form a mucilaginous solution; the resin fraction may not fully dissolve in water alone.
100-150 mL, 2 times daily
2 times daily
As directed by practitioner
Consult Ayurvedic practitioner
Water-based decoction primarily extracts the gum (polysaccharide) fraction and water-soluble components. Boswellic acids, being lipophilic, are poorly extracted by water alone. This preparation may be less effective for anti-inflammatory applications compared to alcoholic extracts or standardized capsules. However, it is a traditional preparation method and the gum fraction may have its own immunomodulatory effects. In Ayurvedic practice, boswellia is often combined with other herbs in multi-ingredient formulations (kashaya/decoctions).
[14]
topical-preparation
Strength: 5-10% boswellia extract in carrier oil or cream base
For external application: Mix powdered boswellia resin or standardized extract with a carrier base (coconut oil, sesame oil, beeswax cream base). A typical formulation uses 5-10% boswellia extract in the carrier. Alternatively, use commercially available boswellia-containing topical creams or gels.
Apply to affected area 2-3 times daily. Massage gently into skin over painful joints or muscles.
2-3 times daily
As needed for local inflammatory conditions
Patch test first. Use at half concentration for children over 6.
Topical application delivers boswellic acids directly to the site of inflammation, bypassing oral bioavailability challenges. Some clinical evidence supports topical boswellia for localized joint and musculoskeletal pain. In Ayurvedic practice, sesame oil is the traditional carrier oil for external applications (taila preparations). Topical use can be combined with oral supplementation for enhanced effect on localized conditions.
[14]
Essential Oil
Strength: Pure steam-distilled essential oil
Steam-distilled essential oil from Boswellia serrata oleo-gum-resin. For external use: dilute 2-3 drops in 15 mL carrier oil. For aromatherapy/inhalation: add 3-5 drops to diffuser. For traditional incense use: burn crude resin on charcoal.
External: 2-3% dilution in carrier oil for massage. Aromatherapy: 3-5 drops in diffuser. NOT for internal use.
Apply topically 2-3 times daily for musculoskeletal pain. Aromatherapy: as needed.
As needed
Aromatherapy only for children over 6 at half adult concentration. Not for topical or internal use in children without professional guidance.
Essential oil contains monoterpenes and sesquiterpenes (alpha-thujene, alpha-pinene, limonene, incensole) but NOT boswellic acids, which are non-volatile triterpenes. Therefore, frankincense essential oil has a different therapeutic profile than oral boswellia extracts. Useful for aromatherapy (calming, anxiety-reducing effects possibly mediated by incensole acetate via TRPV3 receptors) and external warming/rubefacient application. The traditional practice of burning frankincense resin as incense releases volatile compounds including incensole acetate. Essential oil quality varies significantly between Boswellia species; B. carterii and B. sacra oils are more common commercially than B. serrata oil.
[26]
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Rare but documented. Allergic contact dermatitis has been reported from occupational or topical exposure to frankincense resin. Cross-reactivity with other Burseraceae members (myrrh, elemi) is theoretically possible. Discontinue immediately if allergic reaction occurs.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, etc.) (Non-steroidal anti-inflammatory drugs) | theoretical | Boswellia inhibits 5-LOX (leukotriene pathway) while NSAIDs inhibit COX-1/COX-2 (prostaglandin pathway). These are complementary rather than overlapping mechanisms. Additive anti-inflammatory effect is possible. No pharmacokinetic interaction expected. |
| Immunosuppressants (azathioprine, methotrexate, cyclosporine, biologics) (Immunosuppressant agents) | theoretical | Boswellia has immunomodulatory properties (NF-kB inhibition, cytokine modulation, complement inhibition). Theoretical potential for additive immunomodulatory effects or interference with immunosuppressive drug efficacy. The interaction could be synergistic (enhanced immunosuppression) or antagonistic (immune stimulation by gum polysaccharides counteracting immunosuppression). |
| Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel) (Anticoagulants/antiplatelets) | theoretical | Some in vitro evidence suggests boswellic acids may inhibit platelet aggregation. Theoretical potential for additive anticoagulant/antiplatelet effect. Not well-studied clinically. |
| CYP enzyme substrates (various medications metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) (Various (CYP-metabolized drugs)) | theoretical | In vitro studies have shown that some boswellic acids can inhibit certain CYP450 enzymes, which could theoretically affect the metabolism of drugs that are substrates of these enzymes. AKBA has been shown to inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in vitro. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
Pregnancy: No adequate clinical studies of boswellia supplementation during pregnancy. Traditional use of frankincense in food-level amounts (chewing resin) has a long history in Middle Eastern and North African cultures without documented adverse effects, but high-dose standardized extracts have not been evaluated for pregnancy safety. Some animal studies have reported no teratogenic effects, but data are limited. Theoretical concern about immunomodulatory effects during pregnancy. Advise against high-dose supplemental use during pregnancy until more safety data are available. Lactation: No data on excretion of boswellic acids into breast milk. Traditional food-level use in lactating women has a long history without documented adverse effects. High-dose supplemental use during lactation has not been studied. Exercise caution and consult healthcare provider.
Adverse Effects
References
Monograph Sources
- [1] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Gummi Boswellii (not yet published for B. serrata; general Boswellia references). World Health Organization, Geneva (2009)
- [2] Committee on Herbal Medicinal Products (HMPC), European Medicines Agency. Assessment report on Boswellia serrata Roxb. ex Colebr., gummi resina. European Medicines Agency (2014)
- [3] National Center for Complementary and Integrative Health (NCCIH). Frankincense (Boswellia). NCCIH, National Institutes of Health (2023)
- [4] Indian Pharmacopoeia Commission. Indian Pharmacopoeia: Boswellia serrata monograph. Government of India, Ministry of Health and Family Welfare (2014)
Clinical Studies
- [5] Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee -- a randomized double blind placebo controlled trial. Phytomedicine (2003) ; 10 : 3-7 . DOI: 10.1078/094471103321648593 . PMID: 12622457
- [6] Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, Dey D, Raychaudhuri SP. A double blind, randomized, placebo controlled study of the efficacy of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther (2008) ; 10 : R85 . DOI: 10.1186/ar2461 . PMID: 18667054
- [7] Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Trimurtulu G, Sarma KV, Raychaudhuri SK, Raychaudhuri SP. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled trial. Int J Med Sci (2010) ; 7 : 366-377 . DOI: 10.7150/ijms.7.366 . PMID: 21060724
- [8] Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, Ammon HP. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res (1997) ; 2 : 37-43 . PMID: 9049593
- [9] Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med (2001) ; 67 : 391-395 . DOI: 10.1055/s-2001-15802 . PMID: 11488449
- [10] Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon HP. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res (1998) ; 3 : 511-514 . PMID: 9810030
- [11] Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol (2001) ; 39 : 11-17 . DOI: 10.1055/s-2001-10708 . PMID: 11215357
- [12] Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, Baastrup J, Stolte M, Schulz HU, Hotz J. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis (2007) ; 22 : 1445-1451 . DOI: 10.1007/s00384-007-0364-1 . PMID: 17764013
- [13] Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther (2020) ; 20 : 225 . DOI: 10.1186/s12906-020-02985-6 . PMID: 32680575
Traditional Texts
- [14] Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone/Elsevier (2013)
- [15] Williamson EM. Potter's Herbal Cyclopedia. C.W. Daniel Company (2003)
- [16] Metwaly AM, Ghoneim MM, Eissa IH, Elsehemy IA, Mostafa AE, Hegazy MM, Afifi WM, Dou D. Traditional ancient Egyptian medicine: A review. Saudi J Biol Sci (2021) ; 28(10) : 5823-5832 . DOI: 10.1016/j.sjbs.2021.06.044 . PMID: 34588897
- [17] Groom N. Frankincense and Myrrh: A Study of the Arabian Incense Trade. Longman, London (1981) . ISBN: 978-0-582-76476-7
- [18] Moussaieff A, Mechoulam R. Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol (2009) ; 61(10) : 1281-1293 . DOI: 10.1211/jpp/61.10.0003 . PMID: 19814859
- [19] Mahdizadeh S, Khaleghi Ghadiri M, Gorji A. Avicenna's Canon of Medicine: a review of analgesics and anti-inflammatory substances. Avicenna J Phytomed (2015) ; 5(3) : 182-202 . PMID: 26101752
- [20] Siddiqui MZ. Boswellia Serrata, A Potential Antiinflammatory Agent: An Overview. Indian J Pharm Sci (2011) ; 73(3) : 255-261 . DOI: 10.4103/0250-474X.93507 . PMID: 22457547
- [21] Samuelsson G, Farah MH, Claeson P, Hagos M, Thulin M, Hedberg O, Warfa AM, Hassan AO, Elmi AH, Abdurahman AD, et al.. Inventory of plants used in traditional medicine in Somalia. II. Plants of the families Combretaceae to Labiatae. J Ethnopharmacol (1992) ; 37(1) : 47-70 . DOI: 10.1016/0378-8741(92)90004-b . PMID: 1453703
- [22] Hamidpour R, Hamidpour S, Hamidpour M, Shahlari M. Frankincense (Boswellia Species): From the Selection of Traditional Applications to the Novel Phytotherapy for the Prevention and Treatment of Serious Diseases. J Tradit Complement Med (2013) ; 3(4) : 221-226 . DOI: 10.4103/2225-4110.119723 . PMID: 24716181
Pharmacopeias & Reviews
- [23] Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med (2006) ; 72 : 1100-1116 . DOI: 10.1055/s-2006-947227 . PMID: 17024588
- [24] Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet (2011) ; 50 : 349-369 . DOI: 10.2165/11586800-000000000-00000 . PMID: 21553931
- [25] Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther (1992) ; 261 : 1143-1146 . PMID: 1602379
- [26] Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, Kashman Y, Huang SM, Lee H, Shohami E, Mackie K, Caterina MJ, Walker JM, Fride E, Mechoulam R. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J (2008) ; 22 : 3024-3034 . DOI: 10.1096/fj.07-101865 . PMID: 18492727
Last updated: 2026-02-26 | Status: review